InterCure Ltd.
InterCure Ltd. (INCR) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
incr · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
InterCure Ltd.You INCR | $54M | N/A | — | — |
 American Well Corporation AMWL | $146M | N/A | — | -$5.96 |
 Assertio Holdings, Inc. ASRT | $151M | N/A | — | -$4.74 |
 Biomea Fusion, Inc. BMEA | $71M | N/A | — | -$1.18 |
 CAMP4 Therapeutics Corporation CAMP | $90M | N/A | — | -$2.65 |
 Cardiol Therapeutics Inc. CRDL | $121M | N/A | — | -$0.39 |
 Edap Tms S.a. EDAP | $178M | N/A | — | -$0.78 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for InterCure Ltd. (INCR) measures how much investors pay for each dollar of the company's trailing earnings. INCR's current PE ratio of N/A is calculated by dividing its stock price of $0.99 by its TTM earnings per share of —.
Frequently asked questions
INCR pe ratio · 6 questionsINCR's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.99 and TTM EPS of —. Data sourced from Financial Modeling Prep via INCR's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · InterCure Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09